Merus Announces Business Update Conference Call

Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Netherlands ,Madrid ,Spain ,American ,Andrew Joe ,Zenocutuzumab Zeno ,Alison Schram ,Early Access Program ,European Society For Medical Oncology Congress ,Company Conference Call ,Sasia Congress ,American Association Of Cancer Research Annual Meeting ,Exchange Commission ,Memorial Sloan Kettering Cancer Center ,European Society ,Medical Oncology Congress ,Principal Investigator ,Spain October ,Chief Medical Officer ,Oral Presentation Title ,Presentation Details ,Presentation Title ,Poster Session ,American Association ,Cancer Research Annual Meeting ,Bill Lundberg ,Chief Executive Officer ,Singapore December ,Conference Call ,Private Securities Litigation Reform Act ,Quarterly Report ,Nasdaq Mrus ,Merusnv ,Serus ,